The combination of novel immune checkpoints HHLA2 and ICOSLG:A new system to predict survival and immune features in esophageal squamous cell carcinoma

作     者：Chaoqi Zhang Feng Wang Nan Sun Zhen Zhang Guochao Zhang Zhihui Zhang Yuejun Luo Yun Che Hong Cheng Jiagen Li Jie He 

作者机构：Department of Thoracic SurgeryNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021PR China Biotherapy CenterThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenan 450052PR China 

出 版 物：《Genes & Diseases》 (基因与疾病（英文）)

年 卷 期：2022年第9卷第2期

页      面：415-428页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This work was supported by the CAMS Innovation Fund for Medical Sciences(No.2017-I2M-1-005,2016-I2M-1-001) the National Key R&D Program of China(No.2016YFC1303201) the National Natural Science Foundation of China(No.81802299,81502514) the Fundamental Research Funds for the Central Universities(No.3332018070) the National Key Basic Research Development Plan(No.2018YFC1312105) 

主　　题：Esophageal cancer HHLA2 ICOSLG Immune checkpoint Immunotherapy 

摘      要：Studies on immune checkpoint inhibitors targeting B7-CD28 family pathways in esophageal squamous cell carcinoma(ESCC)have shown promising ***,a comprehensive understanding of B7-CD28 family members in ESCC is still *** study aimed to construct a novel B7-CD28 family-based prognosis system to predict survival in patients with *** collected 179 cases from our previously published microarray data and 86 cases with qPCR ***,119 microarray data(GSE53624)were used as a training set,whereas the remaining 60 microarray data(GSE53622),all 179 microarray data(GSE53625)and an independent cohort with 86 qPCR data were used for *** underlying mechanism and immune landscape of the system were also explored using bioinformatics and *** examined 13 well-defined B7-CD28 family members and identified 2 genes(ICSOLG and HHLA2)with the greatest prognostic value.A system based on the combination HHLA2 and ICOSLG(B7-CD28 signature)was constructed to distinguish patients as high-or low-risk of an unfavorable outcome,which was further confirmed as an independent prognostic *** expected,the signature was well validated in the entire cohort and in the independent cohort,as well as in different clinical *** signature was found to be closely related to immune-specific biological processes and ***,high-risk group samples demonstrated high infiltration of Tregs and fibroblasts and distinctive immune checkpoint ***,we built the first,practical B7-CD28 signature for ESCC that could independently identify high-risk *** information may help inform immunotherapy-based treatment decisions for patients with ESCC.